Delisting risk
Cardio Diagnostics
Develops genetic-epigenetic blood tests and clinical intelligence for coronary heart disease.
$1.85
After-hours close+0.03 (+1.65%)
At close$1.82(−2.91%)
Something off on this page? Send us feedback.
Breakdown13F · Form 4
Institutions 9.34%Insiders —
Shares outstanding 2.96M · Float 2.83M · 95.8% free float
Insiders — no current Form 4 position.
Institutions13F, as of Mar 31, 2026
16 holders · 276.4K shares · 6 new positions · 9 increased · 3 reduced · 6 closed
| Holder | Shares | % outstanding | Chg q/q | Filed |
|---|---|---|---|---|
| Jane Street Group, LLC | 81.3K | 2.75% | +81.3Knew | May 12, 2026 |
| HRT Financial LP | 62.5K | 2.11% | +62.5Knew | May 14, 2026 |
| BlackRock, Inc. | 34.7K | 1.17% | −859 | May 13, 2026 |
| Geode Capital Management, LLC | 32.2K | 1.09% | +17.0K | May 15, 2026 |
| Vanguard Capital Management LLC | 20.2K | 0.68% | +20.2Knew | May 15, 2026 |
| Renaissance Technologies LLC | 15.3K | 0.52% | +15.3Knew | May 14, 2026 |
| Scientech Research LLC | 13.9K | 0.47% | +13.9Knew | May 15, 2026 |
| UBS Group AG | 9.9K | 0.34% | +9.0K | May 5, 2026 |
Beneficial owners13D/G · 5% or more, as filed
No 13D/G filer at 5% or more on record.
InsidersForm 4
No current Form 4 position on record.
1 ten-percent owner holds 52.2K shares by Form 4, outside the officers-and-directors figure above · 13 people have not refiled in the last 18 months (136.4K shares), so they are not in the figure above
Latest trades
No open-market trades in the last 12 months.
CongressHouse and Senate disclosures
Not reported.